Chinese Innovative Drugs Accelerate Global Expansion

Chinese innovative drugs are reshaping the global pharmaceutical landscape at an unprecedented pace. In the first half of 2026, Chinese pharmaceutical companies completed 81 out-licensing transactions totaling approximately $110 billion, exceeding 80% of the full-year 2025 total and more than doubling the 2024 figure, according to data from China’s National Medical Products Administration (NMPA) reported by Xinhua News.

A Transformative Shift in Global Pharma

The licensing deals span 10 major therapeutic areas including oncology, metabolism, immunology, and neurology, with licensees coming from more than 20 countries and regions including the United States, France, the United Kingdom, and Italy. This marks a fundamental transformation for China’s pharmaceutical industry, which has evolved from producing cheap generics to developing innovative drugs that global pharma giants are eager to acquire.

China’s R&D pipeline now accounts for approximately 30% of the global total, ranking second globally after the United States. In H1 2026, 38 innovative drugs were approved for marketing in China, of which 31—over 80%—were domestically developed. Among these, 11 were new-target or new-mechanism drugs, all domestically developed, as SCMP reported.

Record-Breaking Deals Define 2026

The scale of recent partnerships is unprecedented. In January, Shiyao Group signed a strategic R&D collaboration and licensing agreement with AstraZeneca for long-acting peptide drugs with a potential total value of $18.5 billion, including a $1.2 billion upfront payment—setting a new record for Chinese upfront payments in pharma deals, according to AstraZeneca China.

In May, Innovent Biologics signed a global strategic collaboration with Pfizer worth up to $10.5 billion, covering 12 early-stage oncology innovation projects, with a $650 million upfront payment. The same month, Hengrui Pharma signed a global strategic collaboration with Bristol-Myers Squibb worth up to $15.2 billion.

In July, China Biopharmaceutical’s COPD drug TQC3721 was licensed to AstraZeneca for up to $1.9 billion, the largest single-product respiratory deal in China in nearly three years, as detailed in AstraZeneca’s press release.

According to 36Kr, Chinese companies occupied 8 of the top 10 global BD transactions in the first half of 2026—a remarkable feat that underscores China’s emergence as a core innovation force in global pharma.

From Followers to Co-Builders

Perhaps the most significant shift is in how Chinese companies participate in global innovation. “The core value of this agreement lies in the word ‘equality,’” said Zhou Hui, Chief R&D Officer of Oncology Pipeline at Innovent Biologics. “Chinese pharma companies have accelerated from being ‘followers’ in global innovation to becoming ‘co-builders’ walking side by side.”

Chinese companies now participate in joint development, co-commercialization, and profit-sharing with global pharma giants rather than simply selling products. This represents a fundamental evolution from exporting products to exporting capabilities, as Science and Technology Daily reported.

“What supports this change is not just transactional innovation, but the progress in the quality of Chinese innovative drug assets and R&D capabilities,” said Jin Chunlin, Director of the Shanghai Health Development Research Center. “As some fields move from ‘following’ to ‘running alongside,’ and even achieving partial leadership, Chinese companies are beginning to participate in global value creation on a more equal footing.”

Policy Support and Cost Advantages

China’s innovative drug boom is underpinned by sustained policy support and manufacturing cost advantages. The State Council issued the National Health 15th Five-Year Plan in July, providing full-chain support for innovative drug development, as documented on the Chinese government’s official website. The drug price registration system launched in 2025 provides multilingual price certificates supporting international market expansion.

Cost advantages are equally compelling. Domestic cell culture media—a key biopharmaceutical raw material—now costs just over 20 yuan per liter, down from 400-600 yuan per liter when it was monopolized by foreign companies. This dramatic cost reduction, combined with streamlined regulatory processes that compressed clinical trial approval times from 14 months to 30 days, has made Chinese innovative drugs increasingly competitive globally.

Global Recognition and Impact

International recognition is growing. The Wall Street Journal noted that global large pharma companies are turning to China for innovation inspiration, declaring that “China has become a major player in the biotechnology field.” The New York Times observed that expanding the supply of Chinese innovative drugs can both enrich treatment options for global patients and help lower drug prices.

French newspaper Liberation reported that Chinese innovative drugs are priced far lower than comparable European and US products, with some cancer treatments entering French medical insurance saving patients tens of thousands of euros per year.

Henlius’ anti-PD-1 antibody H药 (Serplulimab) received NMPA approval in June for a new gastric cancer perioperative indication, becoming the world’s first and only anti-PD-1 antibody approved for this use. The drug had already generated overseas revenue through licensing deals before domestic approval, as Fosun detailed.

What’s Next

Industry observers expect the momentum to continue. Reuters analysis suggests that licensing Chinese biotech patents is significantly cheaper than in-house R&D, and 2026 is projected to set a new record for Chinese biotech licensing deals. The People’s Daily noted that China’s pharmaceutical industry value-added output grew 6.4% year-on-year in H1 2026, with pharmaceutical export delivery value up 9%.

However, questions remain about sustainability. Debates continue over whether early-stage licensing represents selling promising assets too cheaply, and potential regulatory tightening on biotech technology exports could impact future deals. As China Daily reported, innovative medicines are now considered one of China’s “next new three” export pillars, alongside AI-related products and robotics.

What is clear is that Chinese innovative drugs have moved from the periphery to the center of global pharmaceutical innovation. The trajectory—from following, to running alongside, to leading in select areas—reflects a broader transformation in China’s industrial capabilities that is reshaping the global healthcare landscape.